智通财经APP获悉，先健科技(01302)午前涨超4%。截至发稿，涨4.08%，报1.53港元，成交额2905.31万港元。
消息面上，先健科技发布公告，公司收到国家药品监督管理局的正式书面通知，确认由公司附属公司元心科技（深圳）有限公司自主研发的ICS Elpis可吸收外周球扩覆膜支架系统，进入国家药品监督管理局创新医疗器械特别审查程序。该产品适用于髂总动脉、髂外动脉粥样硬化性狭窄或闭塞病变的治疗，为公司第20个进入国家药品监督管理局该程序的产品。
智通财经APP获悉，先健科技(01302)午前涨超4%。截至发稿，涨4.08%，报1.53港元，成交额2905.31万港元。
消息面上，先健科技发布公告，公司收到国家药品监督管理局的正式书面通知，确认由公司附属公司元心科技（深圳）有限公司自主研发的ICS Elpis可吸收外周球扩覆膜支架系统，进入国家药品监督管理局创新医疗器械特别审查程序。该产品适用于髂总动脉、髂外动脉粥样硬化性狭窄或闭塞病变的治疗，为公司第20个进入国家药品监督管理局该程序的产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.